Negative predictive value for cancer in patients with "gray-Zone" PSA level and prior negative biopsy: Preliminary results with multiparametric 3.0 tesla MR

Journal of Magnetic Resonance Imaging

Volumn 36, Issue 4, 2012, Pages 943-950

  Girometti, Rossano ^a   Bazzocchi, Massimo ^a   Como, Giuseppe ^a   Brondani, Giovanni ^a   Del Pin, Matteo ^a   Frea, Bruno ^a   Martinez, Guillermo ^a   Zuiani, Chiara ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

biopsy; Magnetic Resonance Imaging; negative predictive value; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CELL PROLIFERATION; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION TENSOR IMAGING; FALSE POSITIVE RESULT; HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA; HUMAN; HUMAN TISSUE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; SPECTROSCOPY; TRANSRECTAL ULTRASONOGRAPHY;

AGED; BIOPSY; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84866367422     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.23703     Document Type: Article

References (22)

1. Lawrentschuk N, Fleshner N,. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int 2009; 103: 730-733.
2. Turkbey B, Pinto PA, Mani H, et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection-histopathologic correlation. Radiology 2010; 255: 89-99.
3. Kubota Y, Kamei S, Nakano M, et al. The potential role of prebiopsy magnetic resonance imaging combined with prostate-specific antigen density in the detection of prostate cancer. Int J Urol 2008; 15: 322-327. (Pubitemid 351490143)
4. Beyersdorff D, Taupitz M, Winkelmann B, et al. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology 2002; 224: 701-706. (Pubitemid 34919801)
5. Kumar V, Jagannathan NR, Kumar R, et al. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional 1H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml. NMR Biomed 2007; 20: 11-20. (Pubitemid 46332437)
6. Heidenreich A, Bolla M, Joniau S, et al. Guidelines on prostate cancer. European Association of Urology Web site. 2010. Available at: http://www.uroweb.org/guidelines/. Accessed 2011.
7. Scattoni V, Zlotta A, Montironi R, et al. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 2007; 52: 1309-1322. (Pubitemid 47446019)
8. Cirillo S, Petracchini M, Della Monica P, et al. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours. Clin Radiol 2008; 63: 871-879.
9. Verma S, Rajesh A, Fütterer JJ, et al. Prostate MRI and £D MR spectroscopy: how we do it. AJR Am J Roentgneol 2010; 194: 1414-1426.
10. Groenendaal G, van den Berg CAT, Korporaal JG, et al. Simultaneous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients. Radiother Oncol 2010; 95: 185-190.
11. Mueller-Lisse UG, Scherr MK,. Proton MR Spectroscopy of the prostate. Eur J Radiol 2007; 63: 351-360. (Pubitemid 47321931)
12. Dickinson SI,. Premalignant and malignant prostate lesions: pathologic review. Cancer Control 2010; 17: 214-222.
13. Cheikh AB, Girouin N, Colombel M, et al. Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol 2009; 19: 770-778.
14. Norberg M, Egevad L, Holmberg L, et al. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 1997; 50: 562-566. (Pubitemid 27433216)
15. Hara R, Jo Y, Fuji T, et al. Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy. Urology 2008; 71: 191-195. (Pubitemid 351282351)
16. Umbehr M, Bachmann LM, Held U, et al. Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. Eur Urol 2009; 55: 575-591.
17. Kim CK, Park BK,. Update of prostate magnetic resonance imaging at 3 T. J Comput Assist Tomogr 2008; 32: 163-172. (Pubitemid 351489432)
18. Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer: local staging at 3-T endorectal MR imaging-early experience. Radiology 2006; 238: 184-191. (Pubitemid 43010595)
19. Djavan B, Ravery V, Zlotta A, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 2001; 166: 1679-1683.
20. Kim KH, Kim YB, Lee JK, et al. Pathologic results of radical prostatectomies in patients with simultaneous atypical small-acinar proliferation and prostate cancer. Korean J Urol 2010; 51: 398-402.
21. Heijmink SW, Futterer JJ, Hambrock T, et al. Prostate cancer: body-array versus endorectal coil MR imaging at 3 T-Comparison of image quality, localization, and staging performance. Radiology 2007; 244: 184-195. (Pubitemid 46981973)
22. Torricelli P, Cinquantini F, Ligabue G, et al. Comparative evaluation between external phased array coil at 3 T and endorectal coil at 1.5 T. J Comput Assist Tomogr 2006; 30: 355-361. (Pubitemid 43922249)